Cardiovascular Adverse Events in Patients With Cancer Treated With Bevacizumab: A Meta‐Analysis of More Than 20 000 Patients

BACKGROUND: The monoclonal antibody bevacizumab effectively inhibits angiogenesis in several types of cancers by blocking vascular endothelial growth factor. However, life‐threatening cardiovascular adverse effects could limit its use and may warrant specific follow‐up strategies. METHODS AND RESULT...

Descripción completa

Detalles Bibliográficos
Autores principales: Totzeck, Matthias, Mincu, Raluca Ileana, Rassaf, Tienush
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Systematic Review and Meta‐Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5586462/
https://www.ncbi.nlm.nih.gov/pubmed/28862931
http://dx.doi.org/10.1161/JAHA.117.006278

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5586462/
https://www.ncbi.nlm.nih.gov/pubmed/28862931
http://dx.doi.org/10.1161/JAHA.117.006278

Ejemplares similares